Chondrosarcoma Clinical Trial
Official title:
Randomized Study of Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine
Verified date | June 2017 |
Source | Massachusetts General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary purpose of this study is to determine if the administration of a higher dose would decrease the chance of tumor recurrence, compared to the risk of tumor recurrence with a lower dose. Most of the treatment will be given protons, but participants may receive a small portion of treatment with x-rays, because less radiation is given to the skin with x-rays. This study uses two slightly different doses of radiation It is not clear at this time which of the dose levels is better.
Status | Completed |
Enrollment | 381 |
Est. completion date | May 2015 |
Est. primary completion date | July 2007 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Biopsy proven chordoma. Slides must be reviewed prior to randomization by the central review pathologist - Sites: Intercranial (sphenoid, clivus, petrous, basio-occiput) or cervical spine - Boost target volume less than or equal to 150 - 18 years of age or older - Karnofsky Performance Status > 50 - Neurologic Function of I or II - No evidence of metastases Exclusion Criteria: - Previous radiation to the head or neck that would compromise the ability to deliver the prescribed treatment - Concurrent or prior malignancy unless disease free for 5 or more years - Evidence of metastatic disease - Diabetes mellitus - Major medical illness or psychiatric impairments that in the opinion of the investigator, will prevent administration or completion of the protocol therapy |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Acute Toxicity | 90 days | ||
Secondary | Establish local control rates for both dose schedules. | 5 years | ||
Secondary | To provide date to be used as the basis for choosing the dose of charged particle radiation for chordomas of the base of skull and the cervical spine. | 5 years | ||
Secondary | Late Toxicity | 5 Years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039801 -
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04553692 -
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers
|
Phase 1 | |
Recruiting |
NCT06029218 -
Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy
|
N/A | |
Recruiting |
NCT04040205 -
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
|
Phase 2 | |
Not yet recruiting |
NCT06029478 -
Understanding Engagement Trends in Chondrosarcoma Clinical Trials
|
||
Completed |
NCT01553539 -
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT00004241 -
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
|
Phase 1 | |
Active, not recruiting |
NCT04521686 -
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
|
Phase 1 | |
Recruiting |
NCT03715933 -
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
|
Phase 1 | |
Completed |
NCT02496741 -
Metformin And Chloroquine in IDH1/2-mutated Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
Terminated |
NCT00543712 -
A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)
|
Phase 2 | |
Recruiting |
NCT05861245 -
Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base
|
N/A | |
Completed |
NCT00464620 -
Trial of Dasatinib in Advanced Sarcomas
|
Phase 2 | |
Recruiting |
NCT04278781 -
AG-120 in People With IDH1 Mutant Chondrosarcoma
|
Phase 2 | |
Recruiting |
NCT04055220 -
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
|
N/A | |
Recruiting |
NCT04673942 -
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT01560260 -
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
|
Phase 2 | |
Completed |
NCT01609179 -
IPI-926 Extension Protocol for Continuation of Treatment With IPI-926
|
N/A | |
Recruiting |
NCT06387485 -
A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
|
N/A |